Abstract Search

ea0041gp123 | Neuroendocrinology | ECE2016

A placebo-controlled study to assess the dose-effect of COR-005, a novel somatostatin analogue on plasma glucose regulation compared to octreotide in healthy male subjects

Kutz Klaus , Haschke Manuel , Beglinger Christoph , Dehning Carsten , Cohen Fredric

Somatostatin analogues (SSAs) approved to treat acromegaly tend to suppress postprandial insulin/glucagon secretion and can worsen glucose tolerance. COR-005, a novel SSA, is under investigation for treatment of acromegaly. In rodents, COR-005 effectively inhibits GH secretion with 10,000-fold greater potency compared with insulin release suppression. We sought to determine for the first time the effects of COR-005 on postprandial glucose in humans.The p...

0 shares

ePoster

ea0041ep699 | Growth hormone IGF axis - basic | ECE2016

A placebo-controlled study of repeated subcutaneous doses of COR-005 alone or with octreotide on GHRH-stimulated GH and pharmacokinetics in healthy male subjects

Kutz Klaus , Haschke Manuel , Beglinger Christoph , Liška Jiři , Dehning Carsten , Cohen Fredric

Octreotide is first-line medical therapy for patients with acromegaly. Up to 80% of patients are not satisfactorily controlled on octreotide alone and up to 20% have no response. COR-005 (previously DG3173) is a novel somatostatin analogue under investigation for treatment of acromegaly. COR-005 has high affinity for human somatostatin receptor subtypes 2, 4 and 5.The study was designed to assess pharmacokinetics of escalating doses COR-005 sc tid and co...

0 shares

ePoster

Endocrine Abstracts

A placebo-controlled study to assess the dose-effect of COR-005, a novel somatostatin analogue on plasma glucose regulation compared to octreotide in healthy male subjects

A placebo-controlled study of repeated subcutaneous doses of COR-005 alone or with octreotide on GHRH-stimulated GH and pharmacokinetics in healthy male subjects

BiosciAbstracts